OBJECTIVE: The trajectory of cognitive decline in patients with late-onset Alzheimer's disease varies widely. Genetic variations in CLU, PICALM, and CR1 are associated with Alzheimer's disease, but it is unknown whether they exert their effects by altering cognitive trajectory in elderly individuals at risk for the disease. METHOD: The authors developed a Bayesian model to fit cognitive trajectories in a cohort of elderly subjects and test for genetic effects. They first validated the model's ability to detect the previously established effects of APOE ε4 alleles on age at cognitive decline and of psychosis on the rate of cognitive decline in 802 subjects from the Cardiovascular Health Cognition Study who did not have dementia at study entry and developed incident dementia during follow-up. The authors then evaluated the effects of CLU, PICALM, and CR1 on age and rate of decline in 1,831 subjects who did not have dementia at study entry and then did or did not develop incident dementia by study's end. RESULTS: The model generated robust fits to the observed cognitive trajectory data, and validation analysis supported the model's utility. CLU and CR1 were associated with more rapid cognitive decline. PICALM was associated with an earlier age at midpoint of cognitive decline. Associations remained after accounting for the effects of APOE and demographic factors. CONCLUSIONS: Evaluation of cognitive trajectories provides a powerful approach to dissecting genetic effects on the processes leading to cognitive deterioration and Alzheimer's disease.
OBJECTIVE: The trajectory of cognitive decline in patients with late-onset Alzheimer's disease varies widely. Genetic variations in CLU, PICALM, and CR1 are associated with Alzheimer's disease, but it is unknown whether they exert their effects by altering cognitive trajectory in elderly individuals at risk for the disease. METHOD: The authors developed a Bayesian model to fit cognitive trajectories in a cohort of elderly subjects and test for genetic effects. They first validated the model's ability to detect the previously established effects of APOE ε4 alleles on age at cognitive decline and of psychosis on the rate of cognitive decline in 802 subjects from the Cardiovascular Health Cognition Study who did not have dementia at study entry and developed incident dementia during follow-up. The authors then evaluated the effects of CLU, PICALM, and CR1 on age and rate of decline in 1,831 subjects who did not have dementia at study entry and then did or did not develop incident dementia by study's end. RESULTS: The model generated robust fits to the observed cognitive trajectory data, and validation analysis supported the model's utility. CLU and CR1 were associated with more rapid cognitive decline. PICALM was associated with an earlier age at midpoint of cognitive decline. Associations remained after accounting for the effects of APOE and demographic factors. CONCLUSIONS: Evaluation of cognitive trajectories provides a powerful approach to dissecting genetic effects on the processes leading to cognitive deterioration and Alzheimer's disease.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance Journal: Science Date: 1993-08-13 Impact factor: 47.728
Authors: M G Ford; B M Pearse; M K Higgins; Y Vallis; D J Owen; A Gibson; C R Hopkins; P R Evans; H T McMahon Journal: Science Date: 2001-02-09 Impact factor: 47.728
Authors: Oscar L Lopez; Lewis H Kuller; Annette Fitzpatrick; Diane Ives; James T Becker; Norman Beauchamp Journal: Neuroepidemiology Date: 2003 Jan-Feb Impact factor: 3.282
Authors: N Brouwers; C Van Cauwenberghe; S Engelborghs; J-C Lambert; K Bettens; N Le Bastard; F Pasquier; A Gil Montoya; K Peeters; M Mattheijssens; R Vandenberghe; P P De Deyn; M Cruts; P Amouyel; K Sleegers; C Van Broeckhoven Journal: Mol Psychiatry Date: 2011-03-15 Impact factor: 15.992
Authors: Jessica R Marden; Elizabeth R Mayeda; Stefan Walter; Alexandre Vivot; Eric J Tchetgen Tchetgen; Ichiro Kawachi; M Maria Glymour Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: Sandra Barral; Badri N Vardarajan; Dolly Reyes-Dumeyer; Kelley M Faber; Thomas D Bird; Debby Tsuang; David A Bennett; Roger Rosenberg; Bradley F Boeve; Neill R Graff-Radford; Alison M Goate; Martin Farlow; Rafael Lantigua; Martin Z Medrano; Xinbing Wang; M Ilyas Kamboh; Mahmud Muhiedine Barmada; Daniel J Schaid; Tatiana M Foroud; Elise A Weamer; Ruth Ottman; Robert A Sweet; Richard Mayeux Journal: Neurobiol Aging Date: 2015-08-15 Impact factor: 4.673
Authors: Elise A Weamer; Mary Ann A DeMichele-Sweet; Yona K Cloonan; Oscar L Lopez; Robert A Sweet Journal: J Clin Psychiatry Date: 2016-12 Impact factor: 4.384
Authors: Samrachana Adhikari; Fabrizio Lecci; James T Becker; Brian W Junker; Lewis H Kuller; Oscar L Lopez; Ryan J Tibshirani Journal: Stat Med Date: 2019-01-30 Impact factor: 2.373
Authors: Minerva M Carrasquillo; Julia E Crook; Otto Pedraza; Colleen S Thomas; V Shane Pankratz; Mariet Allen; Thuy Nguyen; Kimberly G Malphrus; Li Ma; Gina D Bisceglio; Rosebud O Roberts; John A Lucas; Glenn E Smith; Robert J Ivnik; Mary M Machulda; Neill R Graff-Radford; Ronald C Petersen; Steven G Younkin; Nilüfer Ertekin-Taner Journal: Neurobiol Aging Date: 2014-08-04 Impact factor: 4.673